awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q37143744-5FDEE431-D808-4015-8C0B-F40653EF9358
Q37143744-5FDEE431-D808-4015-8C0B-F40653EF9358
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37143744-5FDEE431-D808-4015-8C0B-F40653EF9358
Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.
P2860
Q37143744-5FDEE431-D808-4015-8C0B-F40653EF9358
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37143744-5FDEE431-D808-4015-8C0B-F40653EF9358
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b897e5330fdbc6b47fce6249939a60611c29e22e
P2860
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.